The clinical trial, sponsored by Professor Nelly Pitteloud at the Centre Hospitalier Universitaire Vaudois, investigates the efficacy of pulsatile GnRH therapy in improving cognitive and olfactory functions in adults with Down syndrome (DS). Given the increasing life expectancy of DS individuals and the lack of existing treatments for cognitive decline and olfactory defects, this study addresses a significant unmet medical need. If successful, the therapy could capture a niche market within the broader neurodegenerative disease landscape, particularly targeting cognitive dysfunction associated with early Alzheimer's disease in DS. The potential for market entry is bolstered by the absence of direct competitors focusing on this specific indication, although broader cognitive enhancement therapies may pose indirect competition. Diligence should focus on regulatory pathways, reimbursement strategies, and the scalability of treatment delivery via subcutaneous pumps.